Ingelheim, 14 August 2012 – The pharmaceutical company Boehringer Ingelheim has grown again in the current financial year. In the first half of 2012, currency-adjusted sales increased by 6.8% compared with the previous year to €7.1 billion. The increased sales were driven by the established respiratory tract medication SPIRIVA® and COMBIVENT®, both of which experienced double-digit growth, as well as by the newly introduced anticoagulant PRADAXA® and the new diabetes medication TRAJENTA®. The company achieved strong growth particularly in the USA and emerging markets. Boehringer Ingelheim is aiming for single-digit growth for the year as a whole. The company’s sales in 2011 amounted to €13.2 billion.